Figure 1

Study design. Patients with postoperative high-risk squamous cell carcinoma of the oral cavity were randomized to receive either cisplatin at 100 mg/m² once every 3 weeks (arm A) or cisplatin at 40 mg/m² once per week (arm B). Abbreviations: CCRT = concurrent chemoradiotherapy.